| Literature DB >> 32725991 |
Joo Myung Lee1, Ki Hong Choi1, Joon Hyung Doh2, Chang Wook Nam3, Eun Seok Shin4, Masahiro Hoshino5, Tadashi Murai5, Taishi Yonetsu6, Hernán Mejía-Rentería7, Tsunekazu Kakuta5, Javier Escaned7,8, Bon Kwon Koo9,10.
Abstract
BACKGROUND AND OBJECTIVES: Recent guideline recommends evaluation using of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) in patients with functionally insignificant stenosis. We evaluated clinical implications of CFR and IMR in patients with high fractional flow reserve (FFR) and deferred revascularization.Entities:
Keywords: Coronary artery disease; Coronary flow reserve; Fractional flow reserve; Index of microcirculatory resistance; Myocardial ischemia; Percutaneous coronary intervention
Year: 2020 PMID: 32725991 PMCID: PMC7515763 DOI: 10.4070/kcj.2020.0083
Source DB: PubMed Journal: Korean Circ J ISSN: 1738-5520 Impact factor: 3.243
General characteristics of deferred population and target vessels
| Characteristics | Total | High FFR | Low FFR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| High CFR | Low CFR | p value | High CFR | Low CFR | p value | ||||
| Per-patient analysis (n=867) | 867 | 546/715 (76.4) | 169/715 (23.6) | 99/152 (65.1) | 53/152 (34.9) | ||||
| General characteristics | |||||||||
| Age (years) | 63.8±10.3 | 63.3±10.4 | 66.1±10.2 | 0.002 | 62.3±9.3 | 65.0±10.4 | 0.101 | ||
| Male | 642 (74.0) | 401 (73.4) | 116 (68.6) | 0.223 | 87 (87.9) | 38 (71.7) | 0.013 | ||
| BMI (kg/m2) | 25.0±3.7 | 24.8±3.8 | 25.0±3.5 | 0.607 | 25.5±3.1 | 25.3±3.5 | 0.707 | ||
| Clinical presentation | 0.266 | 0.177 | |||||||
| Stable ischemic heart disease | 752 (86.7) | 477 (87.4) | 142 (84.0) | 84 (84.8) | 49 (92.5) | ||||
| Acute coronary syndrome | 115 (13.3) | 69 (12.6) | 27 (16.0) | 15 (15.2) | 4 (7.5) | ||||
| Cardiovascular risk factors | |||||||||
| Hypertension | 546 (63.0) | 336 (61.5) | 107 (63.3) | 0.678 | 69 (69.7) | 34 (64.2) | 0.486 | ||
| Diabetes mellitus | 292 (33.7) | 176 (32.2) | 59 (34.9) | 0.517 | 28 (28.3) | 29 (54.7) | 0.001 | ||
| Hypercholesterolemia | 543 (62.6) | 343 (62.8) | 95 (56.2) | 0.123 | 68 (68.7) | 37 (69.8) | 0.886 | ||
| Current smoker | 185 (21.3) | 115 (21.1) | 38 (22.5) | 0.693 | 23 (23.2) | 9 (17.0) | 0.368 | ||
| Obesity (BMI >25 kg/m2) | 392 (46.8) | 243 (45.7) | 73 (45.9) | 0.958 | 51 (52.6) | 25 (50.0) | 0.767 | ||
| Multivessel disease | 365 (42.1) | 203 (37.2) | 84 (49.7) | 0.004 | 49 (49.5) | 29 (54.7) | 0.539 | ||
| SYNTAX score | 7.0 (0.0–13.0) | 5.0 (0.0–10.0) | 5.0 (0.0–10.3) | 0.646 | 12.0 (7.30–19.3) | 14.0 (8.3–22.8) | 0.230 | ||
| Per-vessel analysis (n=1,152) | 1,152 | 747/988 (75.6) | 241/988 (24.4) | 105/164 (64.0) | 59/164 (36.0) | ||||
| Measured vessel location | 0.112 | 0.448 | |||||||
| Left anterior descending artery | 671 (58.2) | 406 (54.4) | 125 (52.3) | 92 (88.5) | 48 (81.4) | ||||
| Left circumflex artery | 212 (18.4) | 140 (18.7) | 59 (24.7) | 7 (6.7) | 6 (10.2) | ||||
| Right coronary artery | 266 (23.1) | 201 (26.9) | 55 (23.0) | 5 (4.8) | 5 (8.5) | ||||
| Quantitative coronary angiography | |||||||||
| Reference diameter (mm) | 3.00±1.25 | 3.02 (2.99–3.07) | 2.92 (2.84–3.00) | 0.024 | 3.18 (2.49–3.87) | 2.64 (2.46–2.82) | 0.138 | ||
| Diameter stenosis (%) | 40.9±15.6 | 39.1 (38.0–40.3) | 41.1 (39.1–43.2) | 0.093 | 47.7 (45.2–50.1) | 51.1 (47.0–55.2) | 0.165 | ||
| Lesion length (mm) | 11.7±7.9 | 11.0 (10.5–11.6) | 12.1 (11.1–13.2) | 0.067 | 13.6 (11.8–15.5) | 15.0 (11.5–18.5) | 0.492 | ||
| Coronary physiologic parameters | |||||||||
| FFR | 0.88±0.07* | 0.90 (0.89–0.90) | 0.89 (0.87–0.90) | 0.222 | 0.76 (0.76–0.77) | 0.75 (0.74–0.77) | 0.153 | ||
| CFR | 3.03±1.28† | 3.58 (3.50–3.66) | 1.54 (1.50–1.58) | <0.001 | 3.38 (3.19–3.58) | 1.53 (1.44–1.62) | <0.001 | ||
| IMR (U) | 17.4 (12.8–24.3) | 20.1 (19.3–20.8) | 25.5 (22.8–28.3) | <0.001 | 15.1 (13.8–16.3) | 19.0 (16.6–21.5) | 0.005 | ||
Values expressed as mean±standard deviation, median (interquartile ranges, 25th–75th), estimated mean (95% confidence interval) (per-vessel analysis), or number (%). Generalized estimating equation model or maximum likelihood χ2 test used for overall and between group comparisons in per-vessel analysis.
BMI = body-mass index; CFR = coronary flow reserve; FFR = fractional flow reserve; IMR = index of microcirculatory resistance; MI = myocardial infarction; PCI = percutaneous coronary intervention.
*FFR: median, 0.88 (Q1–Q3: 0.83–0.93); †CFR: median, 2.86 (Q1–Q3: 2.00–4.00).
Figure 1Distribution of deferred patients according to FFR and CFR.
Distribution of patients with deferred revascularization is presented according to FFR and CFR. Red dots indicate high index of microcirculatory resistance (IMR, ≥23 U). All IMR values corrected by Yong's formula (Pa × Tmn × ([1.35 × Pd/Pa] − 0.32).
CFR = coronary flow reserve; FFR = fractional flow reserve; IMR = index of microcirculatory resistance.
Figure 2Impact of coronary flow reserve on cumulative incidence of clinical outcomes.
Cumulative incidence POCO in patients with (A) low FFR (≤0.80) and (B) high FFR (>0.80), shown by CFR values.
CFR = coronary flow reserve; CI = confidence intervals; FFR = fractional flow reserve; HR = hazard ratio; MI = myocardial infarction; POCO = patient-oriented composite outcome.
Figure 3Distribution of deferred patients with high fractional flow reserve (>0.80) by CFR and IMR.
Since there was weak correlation between CFR and IMR and agreement between the 2 indices was low, therefore, 4 different patterns were observed.
CFR = coronary flow reserve; IMR = index of microcirculatory resistance.
Angiographic and physiologic differences in deferred patients with high FFR, shown by microvascular function
| Characteristics | Group A (CFR >2 and IMR <23 U) | Group B (CFR >2 and IMR ≥23 U) | Group C (CFR ≤2 and IMR <23 U) | Group D (CFR ≤2 and IMR ≥23 U) | p value | ||
|---|---|---|---|---|---|---|---|
| Per-patient analysis (n=715) | 397 (55.5) | 149 (20.8) | 93 (13.0) | 76 (10.6) | |||
| General characteristics | |||||||
| Age (years) | 62.6±10.5 | 65.1±9.6 | 66.1±10.2 | 66.1±10.1 | 0.001 | ||
| Male | 288 (72.5) | 113 (75.8) | 57 (61.3) | 59 (77.6) | 0.054 | ||
| BMI (kg/m2) | 24.6±3.7 | 25.3±4.2 | 24.7±3.2 | 25.4±3.7 | 0.115 | ||
| Clinical presentation | 0.742 | ||||||
| Stable ischemic heart disease | 347 (87.4) | 130 (87.2) | 78 (83.9) | 64 (84.2) | |||
| Acute coronary syndrome | 50 (12.6) | 19 (12.8) | 15 (16.1) | 12 (15.8) | |||
| Cardiovascular risk factors | |||||||
| Hypertension | 242 (61.0) | 94 (63.1) | 54 (58.1) | 53 (69.7) | 0.424 | ||
| Diabetes mellitus | 128 (32.2) | 48 (32.2) | 27 (29.0) | 32 (42.1) | 0.301 | ||
| Hypercholesterolemia | 250 (63.0) | 93 (62.4) | 54 (58.1) | 41 (53.9) | 0.442 | ||
| Current smoker | 79 (19.9) | 36 (24.2) | 15 (16.1) | 23 (30.3) | 0.098 | ||
| Obesity (BMI >25 kg/m2) | 168 (43.8) | 75 (50.7) | 39 (44.3) | 34 (47.9) | 0.518 | ||
| Multivessel disease | 115 (29.0) | 88 (59.1) | 39 (41.9) | 45 (59.2) | <0.001 | ||
| Per-vessel analysis (n=988) | 546 (55.3) | 201 (20.3) | 145 (14.7) | 96 (9.7) | |||
| Angiographic characteristics | |||||||
| Reference diameter | 2.98 (2.93–3.03)†,‡ | 3.15 (3.05–3.26)*,‡ | 2.82 (2.73–2.92)*,†,§ | 3.07 (2.94–3.20)‡ | <0.001 | ||
| Diameter stenosis (%) | 39.1 (37.8–40.5) | 39.2 (37.1–41.3) | 40.9 (38.2–43.6) | 41.5 (38.2–44.8) | 0.411 | ||
| Lesion length (mm) | 11.1 (10.5–11.7)§ | 10.8 (9.9–11.7)§ | 11.8 (10.3–13.2) | 12.6 (11.3–14.0)*,† | 0.145 | ||
| Coronary physiologic parameters | |||||||
| FFR | 0.89 (0.89–0.90)† | 0.91 (0.90–0.92)*,‡ | 0.89 (0.88–0.90)† | 0.90 (0.89–0.91) | 0.001 | ||
| CFR | 3.67 (3.57–3.76)†,‡,§ | 3.34 (3.21–3.48)*,‡,§ | 1.56 (1.50–1.61)*,† | 1.51 (1.45–1.58)*,† | <0.001 | ||
| Resting Tmn (sec) | 0.75 (0.73–0.77)†,‡ | 1.34 (1.27–1.41)*,‡,§ | 0.32 (0.30–0.34)*,†,§ | 0.82 (0.73–0.91)†,‡ | <0.001 | ||
| Hyperemic Tmn (sec) | 0.21 (0.20–0.21)†,§ | 0.41 (0.39–0.43)*,‡,§ | 0.21 (0.20–0.22)†,§ | 0.54 (0.48–0.59)*,†,‡ | <0.001 | ||
| IMR (U) | 15.2 (14.9–15.6)†,§ | 33.2 (31.7–34.6)*,‡,§ | 15.1 (14.5–15.7)†,§ | 41.3 (36.0–46.6)*,‡ | <0.001 | ||
Values expressed as mean±standard deviation (per-patients analysis), estimated mean (95% confidence interval) (per-vessel analysis), or number (%). Generalized estimating equation model or maximum likelihood χ2 test used for overall and between-group comparisons in per-vessel analysis.
CFR = coronary flow reserve; FFR = fractional flow reserve; IMR = index of microcirculatory resistance; MI = myocardial infarction; Pa = aortic pressure; Pd = distal pressure; Tmn = mean transit time.
*p<0.05 vs group A; †p<0.05 vs group B; ‡p<0.05 vs group C; §p<0.05 vs group D.
Figure 4Clinical outcomes by microvascular status, based on CFR and IMR in deferred patients with high fractional flow reserves (>0.80).
Cumulative incidences of (A) patient-oriented composite outcomes and (B) cardiac death or myocardial infarction in 4 patient groups divided by CFR and IMR in patients with deferred revascularization based on high fractional flow reserve (>0.80).
CFR = coronary flow reserve; CI = confidence intervals; HR = hazard ratio; IMR = index of microcirculatory resistance; NA = not applicable; PCI = percutaneous intervention.
Clinical outcomes of deferred patients with high FFR shown by CFR and IMR
| Clinical Outcomes | Group A (CFR >2 and IMR <23 U) | Group B (CFR >2 and IMR ≥23 U) | Group C (CFR ≤2 and IMR <23 U) | Group D (CFR ≤2 and IMR ≥23 U) | p value | ||
|---|---|---|---|---|---|---|---|
| Per-patient analysis (n=715) | 397 (55.5%) | 149 (20.8%) | 93 (13.0%) | 76 (10.6%) | |||
| All-cause death | 2.5% (8) | 2.0% (2) | 1.6% (1) | 7.6% (5) | 0.011 | ||
| Cardiac death | 1.6% (5) | 1.0% (1) | 1.6% (1) | 7.6% (5) | 0.001 | ||
| Myocardial infarction | 0.7% (2) | 1.5% (2) | 2.7% (2) | 4.2% (3) | 0.045 | ||
| Any revascularization | 5.7% (18) | 8.2% (10) | 8.7% (7) | 14.7% (8) | 0.029 | ||
| Target vessel revascularization | 3.2% (10) | 5.4% (7) | 5.4% (4) | 11.2% (6) | 0.091 | ||
| Non-target vessel revascularization | 2.7% (8) | 4.3% (5) | 3.5% (3) | 5.4% (3) | 0.608 | ||
| Cardiac death or myocardial infarction | 2.3% (7) | 2.5% (3) | 4.3% (3) | 10.4% (7) | 0.001 | ||
| Patient-oriented composite outcome* | 8.0% (26) | 10.0% (12) | 10.1% (8) | 21.2% (13) | 0.015 | ||
Data expressed as cumulative incidences of clinical outcomes and number of events. Cumulative incidences of clinical outcomes represent Kaplan-Meier estimates during median follow-up of 1,854.5 days (Q1–Q3, 763.8–1,855.0 days). The p values for log-rank or Breslow test in survival analysis.
CFR = coronary flow reserve; FFR = fractional flow reserve; IMR = index of microcirculatory resistance.
*Patient-oriented composite outcomes include all-cause mortality, any myocardial infarction, and any revascularization.
Independent predictors of patient-oriented composite outcomes* in deferred patients with high FFR
| Models | HR | 95% CI | p value | |
|---|---|---|---|---|
| Model 1 | ||||
| Diabetes mellitus | 2.261 | 1.310–3.905 | 0.003 | |
| Multivessel disease | 1.890 | 1.078–3.316 | 0.026 | |
| Current smoking | 1.198 | 0.607–2.364 | 0.603 | |
| Hypercholesterolemia | 1.155 | 0.650–2.053 | 0.623 | |
| Diameter stenosis | 1.010 | 0.990–1.031 | 0.322 | |
| Lesion length | 1.021 | 0.983–1.061 | 0.290 | |
| Model 2 (Model 1 + low CFR and high IMR) | ||||
| Low CFR and high IMR | 2.282 | 1.176–4.429 | 0.015 | |
| Diabetes mellitus | 2.368 | 1.381–4.061 | 0.002 | |
| Multivessel disease | 1.660 | 0.952–2.896 | 0.074 | |
| Current smoking | 1.121 | 0.591–2.128 | 0.726 | |
| Hypercholesterolemia | 1.305 | 0.733–2.325 | 0.366 | |
| Diameter stenosis | 1.014 | 0.994–1.035 | 0.167 | |
| Lesion length | 1.023 | 0.985–1.061 | 0.236 | |
C-index of models: model 1, 0.674 (95% CI, 0.606–0.742) and model 2, 0.691 (95% CI, 0.618–764); relative integrated discrimination improvement of 0.248 in model 2 (p=0.046).
CFR = coronary flow reserve; CI = confidence interval; HR = hazard ratio; IMR = index of microcirculatory resistance.
*Patient-oriented composite outcomes include all-cause mortality, any myocardial infarction, and any revascularization.